RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $19 | $19 | $19 | $19 |
| % Growth | 0% | 0% | -0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $19 | $19 | $19 | $19 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $324 | $328 | $304 | $484 |
| SG&A Expenses | $324 | $328 | $304 | $484 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $324 | $328 | $304 | $484 |
| Operating Income | -$305 | -$309 | -$284 | -$465 |
| % Margin | -1,589.4% | -1,610.2% | -1,479.9% | -2,423% |
| Other Income/Exp. Net | -$80 | -$82 | -$82 | -$81 |
| Pre-Tax Income | -$385 | -$391 | -$367 | -$546 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$385 | -$391 | -$366 | -$546 |
| % Margin | -2,006.3% | -2,037.5% | -1,907.2% | -2,845.1% |
| EPS | -0.003 | -0.003 | -0.003 | -0.004 |
| % Growth | 0% | -3.8% | 31.6% | – |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.004 |
| Weighted Avg Shares Out | 143,500 | 143,550 | 143,550 | 143,550 |
| Weighted Avg Shares Out Dil | 143,500 | 143,550 | 143,550 | 143,550 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $80 | $82 | $82 | $81 |
| Depreciation & Amortization | $0 | $309 | $284 | $465 |
| EBITDA | -$305 | -$0 | $0 | -$0 |
| % Margin | -1,589.3% | -0.8% | 2.4% | -0.8% |